The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -3,037,420 | -7,279,395 |
| Depreciation | 24,051 | 8,370 |
| Amortization expense | 157,541 | 315,082 |
| Stock-based compensation | 52,987 | 156,203 |
| Change in fair value of warrant liabilities | -46,870 | -68,431 |
| Realized foreign currency translation loss from dissolution of subsidiaries | 0 | -7,171 |
| Loss on asset write-off | 102,913 | 409 |
| Prepaid expenses | -15,696 | 550,785 |
| Other current assets | -84,777 | -25,103 |
| Lease liabilities | - | 0 |
| Accounts payable and accrued liabilities | -243,700 | 461,630 |
| Net cash used in operating activities | -2,890,025 | -6,924,643 |
| Payments on financed director and officer insurance | 116,145 | 292,824 |
| Proceeds from exercises of pre-funded warrants | 0 | 871 |
| Proceeds from common stock sales under atm agreement | -2,203,724 | 4,214,506 |
| Proceeds from issuance of common stock | 2,203,724 | 2,010,782 |
| Proceeds from exercises of warrants | 0 | 1,280,000 |
| Net cash provided by financing activities | -116,145 | 7,213,335 |
| Effect of foreign currency translation on cash | 12,670 | 5,631 |
| Net change in cash, cash equivalents, and restricted cash | -2,993,500 | 294,323 |
| Cash and cash equivalents at beginning of period | 6,922,729 | - |
| Cash and cash equivalents at end of period | 4,223,552 | - |
Pasithea Therapeutics Corp. (KTTAW)
Pasithea Therapeutics Corp. (KTTAW)